August 30, 2016 10:54 PM EDT
R&D

Aban­doned in PhI­II, On­cono­va sac­ri­fices more staffers to its sur­vival strat­e­gy

John Carroll

Editor & Founder

Last spring, be­fore Bax­al­ta merged with Shire, the biotech opt­ed to ax its 2012 part­ner­ship with On­cono­va Ther­a­peu­tics $ON­TX on the late-stage blood can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times